PXPulse Podcast
19th September 2024
This podcast episode, AVAC (AIDS Vaccine Advocacy Coalition) takes a deep dive into the twice-yearly injectable LEN for PrEP to share the science, what made PURPOSE 1 a success, and what’s next to ensure effective and equitable delivery of this groundbreaking prevention product.
This episode features perspective from Principal Investigator, Dr. Flavia Kiweewa of Makerere University – Johns Hopkins University (MU-JHU), Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign (TALC), and AVAC’s Executive Director, Mitchell Warren.
#LEN #PrEP results
Press Release | Foster City, Calif. – June 20, 2024- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
2024-2025 HPTN Scholars Program
2024 International
Dr. Rita Nakalega
2024 IMPAACT
Early Career Investigators Award program
Dr. Patience Atuhaire
2023-2024 HPTN Scholar
Award
Dr. Phionah K. Ssemambo
2023 IMPAACT Early Career Investigator Award
Brenda Kakayi
2023-2025 James Hakim International HIV Investigator Mentoring Program (IHIMP) Award
Dr. Ronnie Kasirye